A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis

Linezolid has become a frequent component of treatment regimens for drug-resistant tuberculosis and is a group C drug in the latest World Health Organization treatment guidelines [1]. However, linezolid has a narrow therapeutic index and there is no consensus on the optimal dose for patients with tuberculosis [2, 3]. A better understanding of lung tissue penetration could provide insight into ideal dosing and the utility of linezolid in patients with severe lung lesions. To evaluate target site lung concentrations of linezolid, we utilised the technique of microdialysis, which facilitates the measurement of unbound (pharmacologically active) extracellular drug concentrations at the site of disease.

Source: European Respiratory Journal - February 7, 2018 Category: Respiratory Medicine Authors: Kempker, R. R., Heinrichs, M. T., Nikolaishvili, K., Sabulua, I., Bablishvili, N., Gogishvili, S., Avaliani, Z., Little, B. P., Bernheim, A., Derendorf, H., Blumberg, H. M., Vashakidze, S., Peloquin, C. A. Tags: Respiratory infections and tuberculosis Original Articles: Research letters Source Type: research